The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Helsinn Therapeutics; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda; Tesaro
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; Merck Sharp & Dohme; Nanobiotix; Novartis; Oxford VacMedix; Pfizer; PharmaMar; Roche; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Celgene; Guardant Health; MSD Oncology; Roche
Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; Medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; priME Oncology; Roche; Samsung; Takeda; touchIME
Speakers' Bureau - AbbVie; Abbvie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Prime Oncology; Roche; Samsung; Takeda; touchIME
Research Funding - EMD Serono (Inst); Merck (Inst)
Other Relationship - GRÍFOLS
 
Bernard Doger
No Relationships to Disclose
 
Margarita Majem
No Relationships to Disclose
 
Enric Carcereny
No Relationships to Disclose
 
Matthew Krebs
Honoraria - Roche
Consulting or Advisory Role - Achilles Therapeutics; Janssen; Roche
Speakers' Bureau - Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BerGenBio; BerGenBio
 
Julio Antonio Peguero
Employment - Oncology Consultants
Leadership - Director, Research Department
 
Patricia Roxburgh
Honoraria - GlaxoSmithKline
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst); Athenex (Inst); Clovis Oncology (Inst); FORMA Therapeutics (Inst); Immutep (Inst); Iovance Biotherapeutics (Inst); Nucana (Inst); PsiOxus Therapeutics (Inst); Replimune (Inst); Sierra Oncology (Inst); Starpharma (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Martin Forster
No Relationships to Disclose
 
Pawan Bajaj
No Relationships to Disclose
 
Timothy Dudley Clay
Honoraria - AstraZeneca; Novartis; Roche
Speakers' Bureau - AstraZeneca; Novartis; Novartis
Research Funding - Bayer (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); Clovis Oncology (Inst); Exelixis (Inst); Immutep (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Roche/Genentech
 
Frederic Triebel
Employment - Immutep
Stock and Other Ownership Interests - Immutep
Patents, Royalties, Other Intellectual Property - Being an inventor on patents on LAG-3 owned by Immutep SAS